Inactive Instrument

Highlights Suda Ltd Australian S.E.

Equities

EMS

AU000000EMS2

End-of-day quote Australian S.E. Other stock markets
- ^AUD	-

Mar. 26	Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise	MT
Mar. 20	Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise	Mar. 25	MT
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	Mar. 19	MT
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Arovella Therapeutics Secures AU$2 Million Tax Rebate for Fiscal Year 2023	Nov. 20	MT
Arovella Therapeutics Secures License for Tumor Targeting Antibody; Shares Fall 6%	23-10-11	MT
Arovella Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-22	CI
Arovella Therapeutics Limited and Imugene Announces Collaboration Advances to Next Phase of Testing	23-02-09	CI
Arovella Therapeutics Secures Exclusive Option to License Cytokine Technology for Cancer Therapy Platform	22-12-20	MT
Arovella Therapeutics Ltd Options Cytokine Technology to Enhance iNKT platform	22-12-19	CI
Arovella Therapeutics Receives R&D Tax Rebate	22-11-29	MT
Arovella Therapeutics Limited Announces Europe Patent to Be Granted for Inkt Cell Therapy Platform	22-11-06	CI
Arovella Therapeutics Ltd Collaborates with Imugene Limited Using its OnCARlytics Platform	22-09-25	CI
Arovella Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-30	CI
Arovella Therapeutics Limited Provides Sumatriptan Update	22-06-27	CI
Arovella Therapeutics Partner STADA Begins Commercial Launch of Insomnia Drug in Australia	22-06-21	MT
Arovella Therapeutics Limited Announces ZolpiMist Launch Australia	22-06-21	CI
Arovella Therapeutics Adopts WEF Framework for ESG Reporting	22-06-09	MT
Arovella Therapeutics Limited Signs Services Agreement with Qimr Berghofer Medical Research Institute to Manufacture its Inkt Cell Therapy for Clinical Trails	22-04-19	CI
Arovella Therapeutics Ltd Announces That the US Patent and Trademark Office Has Accepted Its Patent Application Covering Anagrelide and the Patent Will Proceed to Grant	22-04-05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Suda Ltd Australian S.E.

Equities

EMS

AU000000EMS2

Highlights

Filters